CELYAD S.A.: Celyad CEO to present at the 2016 Cell & Gene Meeting on the Mesa
September 15 2016 - 1:04AM
Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a leader in
the discovery and development of engineered cell therapies, today
announced that Dr. Christian Homsy, Chief Executive Officer,
will present and participate in a panel discussion at the upcoming
Gene and Cell Therapy Meeting on the Mesa being held October 5-7,
2016 in La Jolla, CA, USA.
Dr. Homsy will present during the Partnering Forum event on
Wednesday, October 5, 2015 at 11:15 a.m. Pacific Time. He will
discuss Celyad's recent developments and clinical progress of the
engineered T-cell product candidate, NKR-2, for the treatment of
cancer.
Dr. Christian Homsy, CEO of Celyad, commented, "I am excited to
present our unique natural killer receptor T-cell asset and
participate in the panel discussion at Meeting on the Mesa, one of
the preeminent conferences in our industry. I look forward to
sharing the stage with fellow leaders in the CAR-T field to discuss
some of the opportunities and challenges facing our industry."
Organized by the Alliance for Regenerative Medicine (ARM) and
the Sanford Consortium for Regenerative Medicine, the Cell &
Gene Meeting on the Mesa is a three-day conference bringing
together senior executives from the cell and gene therapy and the
scientific communities to discuss the most pressing issues facing
the sector.
For more information, please contact:
For Europe: Consilium Strategic Communications Amber
Fennell, Chris Gardner, Chris Welsh, and Laura
Thornton - T: +44 (0)20 3709 5700 -
celyad@consilium-comms.com |
For France: NewCap Pierre Laurent and
Nicolas Mérigeau - T: + 33(0)1 44 71 94 94 -
celyad@newcap.eu |
For Belgium: Comfi Gunther De Backer: t.: +32 (0)2 290 90
90 - gunther@comfi.be |
Celyad EU: Christian Homsy, CEO and Patrick
Jeanmart, CFO: T: +32 (0)10 39 41 00
investors@celyad.com US: Graham Morrell, VP
Investor Relations & Communication: gmorrell@celyad.com |
To subscribe to Celyad's newsletter, visit
www.celyad.com Follow us on LinkedIn & Twitter
@CelyadSA
About Celyad
Celyad is a clinical-stage biopharmaceutical company focused on
the development of specialized cell-based therapies. The Company
utilizes its expertise in cell engineering to target severe
diseases with significant unmet need, including cancer. Celyad's
Natural Killer Receptor based T-Cell (NKR-T) platform has the
potential to treat a broad range of solid and liquid tumors. Its
lead oncology candidate, NKR-2, is currently being evaluated in a
Phase I/IIa clinical trial. In addition, Celyad has completed a
Phase III trial in the EU for its C-Cure® cardiovascular disease
candidate in ischemic heart failure. Celyad was founded in 2007 and
is based in Mont-Saint-Guibert, Belgium, and Boston, Massachusetts.
Celyad's ordinary shares are listed on the Euronext Brussels and
Euronext Paris exchanges, and its American Depository Shares are
listed on NASDAQ Global Market, all under the ticker symbol
CYAD.
For more information about Celyad, please visit:
www.celyad.com
Forward looking statements
In addition to historical facts or statements of current
condition, this press release contains forward-looking statements,
including statements about the potential safety and feasibility of
NKR-2 T-cell therapy and C-Cure and the clinical potential of the
Company's technology platform generally and the timing of future
clinical trials, which reflect our current expectations and
projections about future events, and involve certain known and
unknown risks, uncertainties and assumptions that could cause
actual results or events to differ materially from those expressed
or implied by the forward-looking statements.
In particular, it should be noted that the safety data described
in the release are preliminary in nature and the Phase 1 trial is
not completed. There is limited data concerning safety and
feasibility of NKR-2. These data may not continue for these
subjects or be repeated or observed in ongoing or future studies
involving our NKR-2 therapy, C-Cure or other product candidates. It
is possible that safety issues or adverse events may arise in the
future.
These forward-looking statements are further qualified by
important factors, which could cause actual results to differ
materially from those in the forward-looking statements, including
risks associated with conducting clinical trials; the risk that
safety, bioactivity, feasibility and/or efficacy demonstrated
in earlier clinical or pre-clinical studies may not be replicated
in subsequent studies; risk associated with the timely submission
and approval of anticipated regulatory filings; the successful
initiation and completion of clinical trials, including Phase III
clinical trials for C-Cure® and Phase I clinical trial for NKR-2;
risks associated with the satisfaction of regulatory and other
requirements; risks associated with the actions of regulatory
bodies and other governmental authorities; risks associated with
obtaining, maintaining and protecting intellectual property, our
ability to enforce our patents against infringers and defend our
patent portfolio against challenges from third parties; risks
associated with competition from others developing products for
similar uses; risks associated with our ability to manage operating
expenses;, and risks associated with our ability to obtain
additional funding to support our business activities and establish
and maintain strategic business alliances and business initiatives.
A further list and description of these risks, uncertainties and
other risks can be found in the Company's Securities and Exchange
Commission filings and reports, including in the Company's
prospectus filed with the SEC on June 19, 2015 and future filings
and reports by the Company. Given these uncertainties, the reader
is advised not to place any undue reliance on such forward-looking
statements. These forward-looking statements speak only as of the
date of publication of this document. The Company expressly
disclaims any obligation to update any such forward-looking
statements in this document to reflect any change in its
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based,
unless required by law or regulation.
C3BS-CQR-1, C-Cure®, NKG2D CAR T-cell, NKR-2, C-CathezTM,
Celyad, CHART-1, CHART-2 and OnCyte logos are signs internationally
protected under applicable Intellectual Property Laws. Mayo Clinic
holds equity in Celyad as a result of intellectual property
licensed to the Company.
Celyad Oncology (EU:CYAD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Celyad Oncology (EU:CYAD)
Historical Stock Chart
From Jul 2023 to Jul 2024